Skip to main content

Advertisement

SpringerLink
Log in

Liposomal formulations of cytotoxic drugs

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Liposomes are microscopic particles of lipid bilayer membrane that enclose aqueous internal compartments. These drug-delivery systems offer a very interesting opportunity for delivering cytotoxic drugs with equal or improved clinical efficacy and reduced toxicity. The most important clinical application of liposomes until now has been the inclusion of amphotericin B. At the same dose level, liposomal amphotericin B is as effective or slightly less effectivc than the conventional formulation, but much higher dosages, up to 5–7 mg kg−1day−1, can be given with acceptable toxicity. There are three preparations of cytotoxic drugs in an advanced stage of commercial development. Two of these (Doxil and TLD D99) contain doxorubicin and the other (DaunoXome) contains daunorubicin. The cardiac toxicity of the three preparations under clinical evaluation appears to be low in comparison with conventional doxorubicin or daunorubicin. No direct comparisons between the new formulations are available, so it is not yet possible to make any statements concerning their relative efficacy and toxicity. DaunoXome is the only drug that is approved in any country, and is also the best documented. It is too early to make recommendations concerning the place of these drugs in therapy. The marked increase in concentrations at the site of the tumour has yet to lead to increased therapeutic efficacy. These findings need further investigation. The efficacy of liposomal preparations in Kaposi's sarcoma appears to be similar to that of standard therapy and the clinical tolerance is good. Perhaps combination therapy with other cytotoxic agents could result in improved clinical efficacy. Their cost will probably be high in comparison with standard therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bogner JR, Kronawitter U, Rolinski R, Truebenbach K, Goebel FD (1994) Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J Acquired Immune Deficiency Syndrome 7:463–468

    Google Scholar 

  2. Codde JP, Lumsden AJ, Napoli S, Burton MA, Gray BN (1993) A comparative study of the anticancer efficacy of doxorubicin carrying microspheres and liposomes using a rat liver model. Anticancer Res 13:539–543

    PubMed  Google Scholar 

  3. Coker RJ, James ND, Stewart JSW (1993) Hepatic toxicity of liposomal encapsulated doxorubicin. Lancet 341:756

    Google Scholar 

  4. De Marie S, Janknegt R, Bakker-Woudenberg IAJM (1994) Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother 33:907–916

    PubMed  Google Scholar 

  5. Fonseca GA, Valero V, Buzdar A, Walters R, Wiley J (1995) Decreased cardiac toxicity by TLC D-99 (liposomal doxorubicin) in the treatment of metastatic breast carcinoma (abstract). Proc Am Soc Clin Oncol Annu Meet 21: Abstract 96

  6. Fonseca GA, Valero V, Buzdar A, Walters R, Wiley J (1995) Phase II study of TLC D99 (liposomal doxorubicin) in patients with metastatic breast cancer (abstract). Proc Am Soc Clin Oncol Annu Meet 21: Abstract

  7. Forssen EA, Ross ME (1994) DaunoXome treatment of solid tumors: preclinical and clinical investigations. J Liposome Res 4:481–512

    Google Scholar 

  8. Gabizon A, Catane R, Uziely B, Kaufman B, Sarra T, Cohen R, Martin F, Huang A, Barenholz Y (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethyleneglycol coated liposomes. Cancer Res 54:987–992

    PubMed  Google Scholar 

  9. Gill PS, Espina BM, Muggia F, Cabriales S (1995) Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 13:996–1003

    PubMed  Google Scholar 

  10. Gray A, Morgan J (1991) Liposomes in haematology. Blood Rev 5:258–272

    PubMed  Google Scholar 

  11. Gregoriadis G (1991) Overview of liposomes. J Antimicrob Chemother 28 [Suppl B]: 39–48

    Google Scholar 

  12. Guaglianone P, Chan K, Delaflor-Weiss E, Hanisch R, Jeffers S, Sharma D, Muggia F (1994) Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest New Drugs 12:103–110

    PubMed  Google Scholar 

  13. Harrison M, Tomlinson D, Stewart S (1995) Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 13:914–920

    PubMed  Google Scholar 

  14. Hengge UR, Brockmeyer NH, Rasshofer R, Goos M (1993) Fatal hepatic toxicity with liposomal doxorubicin. Lancet 341:383–384

    Google Scholar 

  15. Huang SK, Stauffer PR, Hong K, Guo JW, Phillips TL, Huang A (1994) Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res 54:2186–2191

    PubMed  Google Scholar 

  16. James ND, Coker RJ, Tomlinson D, Harris JR, Gompels M, Pinching AJ, Stewart JS (1994) Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS. Clin Oncol R Coll Radiol 6:293–296

    Google Scholar 

  17. Janknegt R, De Marie S, Bakker Woudenberg IAJM, Crommelin DJA (1992) Liposomal and lipid formulations of amphotericin B: clinical pharmacokinetics. Clin Pharmacokinet 23:279–291

    PubMed  Google Scholar 

  18. Kanter PM, Bullard GA, Ginsberg RA, Pilkiewicz PG, Mayer LD, Cullis PR, Pavelic ZP (1993) Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D99) versus free doxorubicin in beagle dogs. In Vivo 7:17–26

    PubMed  Google Scholar 

  19. Kanter PM, Bullard GA, Pilkiewicz PG, Mayer LD, Cullis PR, Pavelic ZP (1993) Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D99): comparison with doxorubicin and empty liposomes in mice and dogs. In Vivo 7:85–95

    PubMed  Google Scholar 

  20. Kanter PM, Klaich GM, Bullard GA, King JM, Bally MB, Mayer LD (1994) Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs. Anticancer Drugs 5:579–590

    PubMed  Google Scholar 

  21. Kayyali R, Marriott C, Wiseman H (1994) Tamoxifen decreases drug efflux from liposomes: relevance to its ability to reverse multidrug resistance in cancer cells? FEBS Lett 344:221–224

    PubMed  Google Scholar 

  22. Kim S (1993) Liposomes as carriers of cancer chemotherapy. Current status and future prospects. Drugs 46:618–638

    PubMed  Google Scholar 

  23. Ning S, Macleod K, Abra RM, Huang AH, Hahn GM (1994) Hyperthermia induces doxorubicin release from non-circulating liposomes and enhances their anti-tumor efficacy. Int J Radiat Oncol Biol Phys 29:827–834

    PubMed  Google Scholar 

  24. 24.Ostro MJ, Cullis PR (1989) Use of liposomes as injectable drug-delivery systems. Am J Hosp Pharm 46:1576–1587

    PubMed  Google Scholar 

  25. Rizzardini G, Vigevani GM, Cremoni L, Pastecchia C, Milazzo F (1995) Liposomal doxorubicin or bleomycin plus vincristine in epidemic Kaposi's sarcoma (abstract). International Congress of Chemotherapy, Montreal, July 1995, abstract 2173

  26. Sharma A, Straubinger RM (1994) Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharmacol Res 11:889–896

    Google Scholar 

  27. Sharma A, Mayhew E, Straubinger RM (1993) Antitumor effect of taxolcontaining liposomes in a taxol-resistant murine tumor model. Cancer Res 53:5877–5881

    PubMed  Google Scholar 

  28. Simpson JK, Miller RF, Spittle MF (1993) Liposomal doxorubicin for treatment of AIDS-related Kaposi's sarcoma. Clin Oncol R Coll Radiol 5:372–374

    PubMed  Google Scholar 

  29. Uziely B, Jeffers S, Isaacson R, Kutsch K, Wei-Tsao D (1995) Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase 1 studies. J Clin Oncol 13:1777–1785

    PubMed  Google Scholar 

  30. Vaage J, Barbera-Guillem E, Abra R, Huang A, Working P (1994) Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 73:1478–1484

    PubMed  Google Scholar 

  31. Williams SS, Alosco TR, Mayhew E, Lasic DD, Martin FJ, Bankert RB (1993) Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res 53:3964–3967

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy and Toxicology, Maasland Ziekenhuis, P.O. Box 5500, NL-6130, MB Sittard, The Netherlands

    Robert Janknegt Ph.D.

Authors
  1. Robert Janknegt Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Presented in part as an invited lecture at the 7th International Symposium: Supportive Care in Cancer, Luxembourg, 20–23 September 1995

Rights and permissions

Reprints and permissions

About this article

Cite this article

Janknegt, R. Liposomal formulations of cytotoxic drugs. Support Care Cancer 4, 298–304 (1996). https://doi.org/10.1007/BF01358884

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01358884

Key words

Search

Navigation